Regulatory and CMC Strategies for Gene and Cell Therapies: Global Perspectives

Abstract

Gene and cell therapies represent a new frontier in modern medicine, offering curative potential for rare, genetic, and otherwise intractable diseases. Unlike conventional biologics or small molecules, these advanced modalities present unique Chemistry, Manufacturing, and Controls (CMC) challenges due to their inherent complexity, patient-specific production workflows, and sensitive functional attributes. Robust CMC strategies are essential to ensure product quality, safety, and efficacy, while also meeting evolving global regulatory expectations. This review provides a comparative analysis of regulatory perspectives from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA, Japan), and harmonized International Council for Harmonisation (ICH) guidelines. Key themes include autologous versus allogeneic manufacturing paradigms, process sensitivity, supply chain logistics, and scalability limitations. Analytical strategies such as potency assay selection, viral vector characterization, and stability assessment are discussed alongside lifecycle management approaches under ICH Q12 and Q14. Case studies of approved therapies—including CAR-T products (Kymriah, Yescarta), AAV-based gene therapy (Zolgensma), and mRNA vaccines—illustrate practical lessons in regulatory engagement, comparability, and accelerated development. Finally, emerging trends such as digital twins, artificial intelligence–enabled analytics, real-time release testing (RTRT), and sustainability considerations are highlighted as future enablers of more efficient and globally harmonized CMC frameworks. By consolidating current regulatory guidance with practical development insights, this review serves as a comprehensive reference for researchers, regulators, and industry stakeholders advancing gene and cell therapies from bench to bedside.

Keywords: Gene therapy; Cell therapy; CMC; Regulatory guidelines; Potency assays; Viral vectors; Advanced Therapy Medicinal Products (ATMPs); ICH harmonization; Real-time release testing; Digital twins